Worked examples, one per modality

Each study takes one series against one target, states what was measured, and shows which liability decided the ranking.

12 February 2026Small molecules
Widening a KRAS G12C series exposure margin from 1.8x to 11x
The compound that advanced was ninth by biochemical potency and first by unbound margin.
Read the case study
4 March 2026Peptides
Extending a stapled MDM2 peptide to 4.1 hours in whole blood
The matrix a peptide was measured in decided which sequences looked stable.
Read the case study
21 April 2026Protein degraders
Separating on-target degradation from SALL4 loss in a CRBN glue series
Equivalent on-target potency, and a fourteen-fold difference in off-target degradation.
Read the case study